TargetBeta
JAK2
Janus kinase 2 · also JTK10 · SH2 domain containing
14 programs in company-led studies act on JAK2, from 13 companies: 6 in phase 3, 5 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (13 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| upadacitinibrule | AbbVie | phase 4 | 6424 running | JAK1, JAK3, TYK2 | ChEMBL |
| ruxolitinibrule | Incyte | phase 4 | 9518 running | JAK1, JAK3, TYK2 | ChEMBL |
| baricitinibrule | Eli Lilly | phase 4 | 598 running | JAK1 | ChEMBL |
| tofacitinibrule | Pfizer | phase 4 | 943 running | JAK1, JAK3, TYK2 | ChEMBL |
| filgotinib maleaterule | Eisai | phase 4 | 21 running | JAK1, JAK3, TYK2 | ChEMBL |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 318 running | FLT3, JAK1, JAK3 | the studies' text |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 464 running | JAK1, JAK3, TYK2 | ChEMBL |
| momelotinibrule | GlaxoSmithKline | phase 3 | 174 running | ACVR1, JAK1 | NCIt |
| flonoltinibrule | Chengdu Zenitar Biomedical Technology | phase 3 | 74 running | CDK6, FLT3 | the studies' text |
| pacritinibrule | Swedish Orphan Biovitrum | phase 3 | 183 running | ACVR1, FLT3, IRAK1 | NCIt |
| delgocitinibrule | LEO Pharma | phase 3 | 212 running | JAK1, JAK3, TYK2 | ChEMBL |
| JAK2 Inhibitor TQ05105 | Sino Biopharmaceutical | phase 2 | 167 running | – | a judged reading |
| flonoltinib maleaterule | Chengdu Zenitar Biomedical Technology | phase 2 | 21 running | FLT3 | NCIt |
| JAK2V617F Inhibitor PRT12396rule | Prelude Therapeutics | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Arthritis, Rheumatoid, 5 programs
- Dermatitis, Atopic, 5 programs
- Primary Myelofibrosis, 5 programs
- Colitis, Ulcerative, 4 programs
- Alopecia Areata, 3 programs
- Arthritis, Juvenile, 3 programs
- COVID-19, 3 programs
- Polycythemia Vera, 3 programs
- Arthritis, Psoriatic, 2 programs
- Crohn Disease, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026upadacitinib · AbbVie · phase 4 · NCT06389136
- Dec 2026baricitinib · Eli Lilly · phase 4 · NCT07843693
- Dec 2026tofacitinib · Pfizer · phase 4 · NCT07843693
- Dec 2026JAK2 Inhibitor TQ05105 · Sino Biopharmaceutical · phase 2 · NCT07708272
- Dec 9, 2026ruxolitinib · Incyte · phase 4 · NCT07049575
- Dec 11, 2026momelotinib · GlaxoSmithKline · phase 3 · NCT03441113
- Dec 30, 2026flonoltinib · Chengdu Zenitar Biomedical Technology · phase 3 · NCT07768111
- Dec 30, 2026pacritinib · Swedish Orphan Biovitrum · phase 3 · NCT06782373
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.